User:Mr. Ibrahem/Deutetrabenazine
 | |
| Clinical data | |
|---|---|
| Trade names | Austedo |
| Other names | Tetrabenazine D6; SD809; SD-809 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617022 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Vesicular monoamine transporter 2 (VMAT2) inhibitor[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H21D6NO3 |
| Molar mass | 323.462 g·mol−1 |
Deutetrabenazine, sold under the brand name Austedo, is a medication used to treat Huntington’s disease associated chorea, tardive dyskinesia, and Tourette's syndrome.[1] It is taken by mouth twice per day.[1]
Common side effects include sleepiness, diarrhea, dry mouth, and trouble sleeping.[2] Other side effects may include QT prolongation, neuroleptic malignant syndrome, and parkinsonism.[2] It should not be used in people with liver problems or who are suicidal.[2] It is a vesicular monoamine transporter 2 (VMAT2) inhibitor.[1]
Deutetrabenazine was approved for medical use in the United States in 2017.[1] In the United States 60 tablets of 12 mg costs about 6,000 USD as of 2021.[3] It is similar to tetrabenazine except it contains deuterium.[1]
References[edit]
- ^ a b c d e f g "Deutetrabenazine Monograph for Professionals". Drugs.com. Retrieved 23 December 2021.
- ^ a b c d "DailyMed - AUSTEDO- deutetrabenazine tablet, coated AUSTEDO- deutetrabenazine kit". dailymed.nlm.nih.gov. Archived from the original on 14 May 2021. Retrieved 23 December 2021.
- ^ "Deutetrabenazine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 23 December 2021.